AUTHORS
Xuechun Wang, MD, Qian Ding2, Jinqiong Li, MD3, Xiao Han4, Zhang Mengyun5, Jincheng Gao, MD6, Cheng Zhang, MD7, Wen Qin, MD8, Xi Zhang, MD9
AFFILIATIONS
1 Xinqiao Hospital of Army Medical University, Chongqing, China
2 The People's Hospital of Guizhou Province, Guiyang, China
3 Lijiang People's Hospital, Yunnan, China
4 Xinqiao Hospital of Army Medical University, Chongqing, China
5 Xinqiao Hospital of Army Medical University, Chongqing, China
6 Xinqiao Hospital of Army Medical University, Chongqing, China
7 Xinqiao Hospital of Army Medical University, Chongqing, China
8 Xinqiao Hospital of Army Medical University, Chongqing, China
9 Xinqiao Hospital of Army Medical University, Chongqing, China
ABSTRACT
Background: Acute promyelocytic leukemia (APL) achieves high cure rates with ATRA+ATO (all-trans retinoic acid + Arsenic Trioxide), yet early mortality remains 8-15% due to coagulopathy and differentiation syndrome (DS). ATO application brings significant toxicities, even fatal complications. Venetoclax (VEN), a BCL-2 inhibitor, shows favorable safety and efficacy in AML and emerging APL reports. Therefore, this study evaluates whether VEN+ATRA can provide a safe, effective induction strategy for newly diagnosed adult APL.
Methods: Adult patients with newly diagnosed APL received VEN+ATRA induction (for WBC ≥4×10?/L, VEN 100?mg qd is given until WBC <4×10?/L; for WBC <4×10?/L, VEN 100?mg qd plus ATRA 25?mg/m²/day for 28?days in total). Assessments include Disseminated Intravascular Coagulation (DIC) and hematologic recovery, transfusion requirements, and adverse events (AE) related to early mortality. Post-induction evaluation includes bone marrow (BM) blast clearance and PML::RARα expression.
Results: From February 10 to July 22, 2026, 18 eligible patients received VEN+ATRA induction. The mean age was 49.2 years (25-70), with 11 males and 7 females. Baseline laboratory values showed a mean WBC 9.7×10?/L (105.6-0.51) and PLT 40.8×10?/L (124-4). Per the 2018 Chinese APL guideline, 2 patients were high-risk (high), 11 intermediate-risk (inter), and 5 low-risk (low). 1. VEN+ATRA induced rapid correction of coagulopathy. 15/17 evaluable patients presented with DIC (CDSS Chinese DIC Scoring System, CDSS ≥ 6). The mean time to coagulation improvement (CDSS ≤ 5) was 6.3 days (low 3.6; inter 6.4; high 10). PT normalization (<15.5s) was achieved within 3-4 days, and 11/18 patients showed no upward trend in PT after treatment initiation, indicating early stabilization of coagulation parameters. 2. VEN+ATRA showed low transfusion requirements. 10/18 patients received plasma (mean 280?mL, range 0-850). 11/18 received cryoprecipitate (mean 7.8?U, range 0-26). 10/18 required fibrinogen supplementation (mean 3.5?g, range 0-22). 9/18 received RBC transfusion (mean 2.25 U). 10/18 required platelet transfusion (mean 2.4 therapeutic doses); notably, no platelet transfusion was needed in low-risk APL. 3. VEN+ATRA shortened hematologic recovery time and length of stay (LOS). Platelet recovery occurred at a mean of 10.8 days (4-26) (low 6.8; inter 10.5; high 22). Hemoglobin recovery averaged 13.9 days (5-33) (low 7; inter 13.1; high 28). ANC (absolute neutrophil count) recovery occurred at 16.9 days (low 14.7; inter 16.4; high 22.5). Mean LOS was 13 days (5-32) (low 9.2; inter 12.2; high 26.5), indicating faster clinical stabilization. 4. VEN+ATRA demonstrated a favorable safety profile. Five patients required antibiotic therapy for infection management; three received voriconazole for empiric treatment, and two received posaconazole prophylaxis. No infectious shock occurred. Except for one high-risk patient (WBC 105.6×10?/L) who received prednisone prophylaxis for DS, no corticosteroids were used in the 17 patients. No DS, hemorrhagic events, Tumor Lysis Syndrome (TLS), hepatic/renal failure, or deaths occurred during induction. 5. VEN+ATRA demonstrated promising therapeutic efficacy. Among 13/18 patients who underwent NGS, WT1 mutations were found in 3, NRAS in 2, ETV6 in 1, FLT3-ITD in 1, and FLT3-TKD in 1 patient. Mean BM blasts decreased from 78.1% at D0 (43-96%) to 16% at D14 (0-68%) and 1% at D28 (0-2.8%). Blast clearance occurred in 4/13 patients by D14 and 6/14 by D28. For PML::RARα, 14 patients underwent quantitative testing and 4 qualitative tests. Mean transcript levels declined from 40.48% at D0 (16.5-79%) to 31.16% at D14 (5.4-70.4%) and 1.446% at D28 (0-15.7%, median 0.068%). Molecular remission (0%) was achieved in 2/12 evaluable patients by D28.
Conclusions: Our findings demonstrate that the VEN+ATRA regimen achieved rapid correction of coagulopathy, low transfusion requirements, and accelerated hematologic recovery, leading to shorter hospitalization and a favorable safety profile without severe adverse events during induction. By day 28, both BM blast burden and PML::RARα transcript levels declined markedly, demonstrating a clear early molecular response. Although larger cohorts, longer follow-up, and randomized controlled studies are needed, VEN+ATRA may represent a safe and effective induction strategy for newly diagnosed adult APL.
DISCLOSURES
Xuechun Wang, MD: No relevant conflicts of interest to declare.